Cargando…

MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN

Lung cancer is the most common diagnosed malignancy and the leading cause of cancer-related mortality worldwide. Murine double minute 2 (MDM2) SNP309 polymorphisms have been reported to influence the risk of lung cancer. However, the published studies together with four subsequent meta-analyses have...

Descripción completa

Detalles Bibliográficos
Autores principales: HE, WENWU, LONG, JIANXIONG, XIAN, LEI, PANG, FENG, SU, LI, WEI, SHIXIU, WEI, BO, HU, YANLING
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501375/
https://www.ncbi.nlm.nih.gov/pubmed/23170107
http://dx.doi.org/10.3892/etm.2012.640
_version_ 1782250181183406080
author HE, WENWU
LONG, JIANXIONG
XIAN, LEI
PANG, FENG
SU, LI
WEI, SHIXIU
WEI, BO
HU, YANLING
author_facet HE, WENWU
LONG, JIANXIONG
XIAN, LEI
PANG, FENG
SU, LI
WEI, SHIXIU
WEI, BO
HU, YANLING
author_sort HE, WENWU
collection PubMed
description Lung cancer is the most common diagnosed malignancy and the leading cause of cancer-related mortality worldwide. Murine double minute 2 (MDM2) SNP309 polymorphisms have been reported to influence the risk of lung cancer. However, the published studies together with four subsequent meta-analyses have yielded contradictory results. To examine this inconsistency, we conducted a meta-analysis of 6,696 lung cancer cases and 7,972 controls from eight published case-control studies using METAGEN. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated with STATA software and used to assess the strength of the association. In the overall analysis, a significant association between MDM2 SNP309 polymorphism and lung cancer risk was observed (OR, 1.143; 95% CI, 1.047–1.247). Moreover, stratified by ethnicity, a significant association was found in Asians (OR, 1.260; 95% CI, 1.111–1.429), but not in Europeans. Subgroup analysis of gender, histology and smoking status suggested that the MDM2 SNP309 genotype was associated with increased lung cancer risk in women (OR, 1.282; 95% CI, 1.062–1.548) and never smokers (OR, 1.328; 95% CI, 1.119–1.575). No statistically significant association was observed in males and ever smoking population, and no association was found in subgroup analysis based on histology. In conclusion, the association between MDM2 SNP309 and lung cancer was statistically significant, particularly in Asians, women and never smoking population.
format Online
Article
Text
id pubmed-3501375
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-35013752013-10-01 MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN HE, WENWU LONG, JIANXIONG XIAN, LEI PANG, FENG SU, LI WEI, SHIXIU WEI, BO HU, YANLING Exp Ther Med Articles Lung cancer is the most common diagnosed malignancy and the leading cause of cancer-related mortality worldwide. Murine double minute 2 (MDM2) SNP309 polymorphisms have been reported to influence the risk of lung cancer. However, the published studies together with four subsequent meta-analyses have yielded contradictory results. To examine this inconsistency, we conducted a meta-analysis of 6,696 lung cancer cases and 7,972 controls from eight published case-control studies using METAGEN. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated with STATA software and used to assess the strength of the association. In the overall analysis, a significant association between MDM2 SNP309 polymorphism and lung cancer risk was observed (OR, 1.143; 95% CI, 1.047–1.247). Moreover, stratified by ethnicity, a significant association was found in Asians (OR, 1.260; 95% CI, 1.111–1.429), but not in Europeans. Subgroup analysis of gender, histology and smoking status suggested that the MDM2 SNP309 genotype was associated with increased lung cancer risk in women (OR, 1.282; 95% CI, 1.062–1.548) and never smokers (OR, 1.328; 95% CI, 1.119–1.575). No statistically significant association was observed in males and ever smoking population, and no association was found in subgroup analysis based on histology. In conclusion, the association between MDM2 SNP309 and lung cancer was statistically significant, particularly in Asians, women and never smoking population. D.A. Spandidos 2012-10 2012-07-18 /pmc/articles/PMC3501375/ /pubmed/23170107 http://dx.doi.org/10.3892/etm.2012.640 Text en Copyright © 2012, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
HE, WENWU
LONG, JIANXIONG
XIAN, LEI
PANG, FENG
SU, LI
WEI, SHIXIU
WEI, BO
HU, YANLING
MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN
title MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN
title_full MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN
title_fullStr MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN
title_full_unstemmed MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN
title_short MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN
title_sort mdm2 snp309 polymorphism is associated with lung cancer risk in women: a meta-analysis using metagen
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501375/
https://www.ncbi.nlm.nih.gov/pubmed/23170107
http://dx.doi.org/10.3892/etm.2012.640
work_keys_str_mv AT hewenwu mdm2snp309polymorphismisassociatedwithlungcancerriskinwomenametaanalysisusingmetagen
AT longjianxiong mdm2snp309polymorphismisassociatedwithlungcancerriskinwomenametaanalysisusingmetagen
AT xianlei mdm2snp309polymorphismisassociatedwithlungcancerriskinwomenametaanalysisusingmetagen
AT pangfeng mdm2snp309polymorphismisassociatedwithlungcancerriskinwomenametaanalysisusingmetagen
AT suli mdm2snp309polymorphismisassociatedwithlungcancerriskinwomenametaanalysisusingmetagen
AT weishixiu mdm2snp309polymorphismisassociatedwithlungcancerriskinwomenametaanalysisusingmetagen
AT weibo mdm2snp309polymorphismisassociatedwithlungcancerriskinwomenametaanalysisusingmetagen
AT huyanling mdm2snp309polymorphismisassociatedwithlungcancerriskinwomenametaanalysisusingmetagen